CRAVE Study: Comparing Craving Responses and Diet Quality of GLP1 Receptor Agonist Users

What this study is testing ClinicalTrials.gov NCT06467604 ↗

Description as written by the study sponsor.

This study aims to assess the impact of GLP-1 receptor agonists, semaglutide and tirzepatide, on food cravings and diet quality in individuals with overweight or obesity. Over 24 weeks, up to 150 adult participants will be monitored using questionnaires and dietary records at 0, 12, and 24 weeks to measure changes in diet quality, disordered eating, food cravings, and hunger. This research, conducted with Seen Medical Group at Knownwell Health Clinic, seeks to fill the gap in literature on the dietary quality effects of GLP-1RAs.

Treatments tested

• Surveys also known as FCI-II, 3 day Food Diary, Hunger VAS, BED-7, HFSS 2-item food insecurity survey, MESA Neighborhood Healthy Food Behavioral

  Participants will be provided electronic surveys at 3 timepoints throughout study.

• Indirect Calorimetry Other

  Participants will receive indirect calorimetry at 3 time points throughout the study.

• Body composition also known as Seca mBCA 554 Other

  Participants will receive body scans using bioelectrical impedence seca mBCA 554 digital body composition analysis scale 3 time points throughout the study.

• Anthropometrics also known as Waist circumference, Height, Weight Other

  Participants will have their Height, weight, waist circumference, and calculated BMI performed at 3 time points throughout the study.